Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Optimizing Frontline Therapy and Maintenance in FL

January 23rd 2018

Frontline Treatment Approaches to Follicular Lymphoma

January 23rd 2018

FL: Monitoring to Initiate Therapy and Gauge Response

January 23rd 2018

Risk Stratification and Outcomes in Follicular Lymphoma

January 23rd 2018

Diagnosis and Staging for Follicular Lymphoma

January 23rd 2018

Brentuximab Vedotin Approved in Europe for CTCL

January 22nd 2018

Brentuximab vedotin (Adcetris) has been approved by the European Commission for the treatment of patients with CD30-positive cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

Celgene Acquiring Juno Therapeutics for $9 Billion

January 22nd 2018

Celgene has announced plans to acquire Juno Therapeutics, maker of the CAR T-cell therapy lisocabtagene maraleucel (JCAR017), for $87 per share, totaling approximately $9 billion.

Dr. Andreadis on the Current State of CAR T-Cell Therapy in Lymphoma

January 22nd 2018

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses chimeric antigen receptor (CAR) T-cell therapy in lymphoma.

Considerations for CAR T-Cell Therapy in NHL

January 19th 2018

Babis Andreadis, MD, discusses the successes seen with CAR T-cell development in the past year and the use of CAR T-cell therapy in patients with NHL.

FDA Grants Tisagenlecleucel Priority Review for DLBCL

January 17th 2018

The FDA has granted a priority review to the CAR T-cell therapy tisagenlecleucel for adult patients with relapsed/refractory DLBCL who are ineligible for or relapse after autologous stem cell transplant.

Axi-Cel Plus Atezolizumab Active, Safe in DLBCL

January 13th 2018

The combination of the CAR T-cell therapy axicabtagene ciloleucel and the PD-L1 inhibitor atezolizumab was highly active with a manageable safety profile in patients with refractory DLBCL enrolled in the phase I/II ZUMA-6 trial.

Cost Effectiveness and Future of CAR T Therapy

January 9th 2018

Evaluating CAR T-Cell Therapy Use

January 9th 2018

Potential for CAR T-Cell Therapy for R/R AML

January 9th 2018

BCMA-Targeted CAR T-Cell Therapy for Myeloma

January 9th 2018

Allogeneic CAR T-Cell Approaches for NHL

January 9th 2018

The Use of CTL019 in Lymphoma

January 9th 2018

JCAR017 for B-Cell NHL

January 9th 2018

Axi-Cel and Future of CAR T-Cell Therapy in Lymphoma

January 9th 2018

Clinical Data for Axi-Cel in Lymphoma

January 9th 2018